X

Drug Profile

Research programme: small molecule therapeutics - Terns Pharmaceuticals

Alternative Names: TERN-800; TERN-800 series

Latest Information Update: 29 Mar 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Terns Pharmaceuticals
Class Obesity therapies; Small molecules
Mechanism of Action Gastric inhibitory polypeptide receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Obesity

Most Recent Events

27 Mar 2023 Preclinical trials in Obesity in USA (PO) (Terns Pharmaceuticals pipeline, March 2023)
02 Mar 2023 Terns Pharmaceuticals plans to initiate IND-enabling activities in 2024
06 Jan 2023 Early research in Obesity in USA (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com